Abiomed Lawsuit

An Abiomed lawsuit was filed in February 2013 and affected holders of Abiomed securities purchased between August 5, 2011, and October 31, 2012. If you purchased Abiomed securities between these dates, you have certain rights under the law. Among these rights is the ability to move to be named lead plaintiff, or representative, of a class of Abiomed securities. You do not have to take any action to join the class, but you must retain your counsel if you wish.

Abiomed sought to induce physicians to use its pumps by buying meals for them

Abiomed started in 1981. Its artificial heart was approved in 2006 and cost nearly $23,000, including the cost of the pump, care, and meals. The company’s chief executive, Michael R. Minogue, was a Bronze Star Gulf War veteran and former General Electric executive who had spent 11 years in the healthcare industry. At the time, the artificial heart sounded like science fiction. At its peak, the partly external heart pump generated $30 million in sales.

To promote the pump, Abiomed bought meals for doctors to get them to use its pump. Abiomed even bought the meals at restaurants with a high price tag to induce physicians to use its pumps. This practice violated the False Claims Act and would be a deception, government officials said. This is illegal because some of the pumps were paid for by the federal government.

Abiomed paid $3.1 million to settle a U.S. probe

Abiomed Inc. settled a federal probe after a whistleblower alleged that the company paid kickbacks to sales representatives for using its Impella pump. The allegations were not proven, but the company agreed to pay over $3.1 million to resolve the case. While the case was still in the early stages, Abiomed has already paid more than $500,000 to the whistleblower.

The investigation focused on claims that Abiomed paid doctors lavish dinners in Beverly Hills to induce them to prescribe its heart pumps. The company also paid for doctors’ spouses to join the events. These expenses were not justified by the doctors’ work, and the money was beyond the company’s budget. Although the company has denied any wrongdoing, the settlement provides evidence that the payments were made to doctors and their staff.

Abiomed misrepresented the number of attendees at physicians’ meals

A federal investigation revealed that Abiomed paid for dinners for physicians’ spouses, who had no legitimate business purpose. The company also overstated the number of attendees at its physician meals by using generic names for employees and adding fictitious names to mask the true cost per person. The company will pay out $542,500 to the whistleblower. The lawsuit was filed by former Abiomed employee Max Bennett.

The government claimed that the meals led to false claims for payments for the Impella heart pumps, which can cost over $20,000 each. The pumps are paid for by Medicare, which is the federal health care program for the elderly and disabled. The government expects the settlement with Abiomed to serve as a warning to other medical device manufacturers. While the company said it had conducted a probe and found that fewer than two percent of its physicians attended meals that exceeded internal guidelines, the fact remains that the number of attendees was false.

Abiomed treated doctors to meals at some of the most expensive U.S. restaurants

Abiomed is a medical device company that sold five Impella heart pumps, which cost an average of $23,000 apiece. This price includes the company’s care and support. In its March 31 fiscal year, Abiomed reported $594 million in revenue. In addition to the SEC investigation, the FBI and the Office of Inspector General of the Department of Health and Human Services both investigated Abiomed’s practices.

The government says that the inflated prices for the Impella heart pump caused false claims for payment from Medicare. The government believes that the meals led physicians to use the devices, which cost upwards of $20,000 apiece. It hopes that the settlement with Abiomed will serve as a warning to other medical device companies. The company says that the settlement will prevent future misconduct.

Abiomed refused to meet with Japan’s PMDA

Abiomed’s CEO, Peter Bolt, points out that the Japanese regulators were very thoughtful and data-driven in their request. They may not require repeating preclinical studies, but they may request a different presentation of dosing selection data and pharmacology studies. While this may seem like a fair trade-off, it is not. Bolt and Suzuki argued that they were not seeking to gain the market share of Japanese companies in the U.S.

In the meantime, the Japanese regulator agreed to waive the requirement for a human clinical study. Before the meeting, Bolt had indicated that the requirement for a human trial was an “overhang.” A human clinical study would require hundreds of subjects, cost millions of dollars, and delay the release of Impella by five to seven years. Abiomed was also planning to invest in the distribution in Japan. Even if Abiomed did not meet with the Japanese regulators, future discussions with the PMDA should proceed smoothly.

Leave a Reply

Your email address will not be published. Required fields are marked *